RCT: In patients with chronic myeloid leukemia in chronic phase resistant/intolerant to ≥2 tyrosine kinase inhibitors, Asciminib resulted in better disease response compared to Bosutinib.
28 Jan, 2022 | 08:00h | UTCNews Release: Asciminib Superior to Bosutinib in Chronic-Phase CML – ASH Clinical News